A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV) (NCT06985147)
A Phase 2, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DISC-3405 in Participants With Polycythemia Vera (PV)
🩺 Plain-English Summary (8th-Grade Level)
This open-label, multicenter, within-participant dose escalation study examining up to 2 dose levels of DISC-3405 will assess the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of DISC-3405 in participants with polycythemia vera (PV).
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic in Arizona — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (15 Sites)
- Mayo Clinic in Arizona — Phoenix, Arizona
- USC Norris Comprehensive Cancer Center — Los Angeles, California
- UCLA Health — Los Angeles, California
- Keck Medicine of USC - Cancer Clinic- Newport Beach — Newport Beach, California
- Mayo Clinic in Florida — Jacksonville, Florida
- Mayo Clinic in Minnesota — Rochester, Minnesota
- Siteman Cancer Center - Washington University St. Louis — St Louis, Missouri
- Atrium Health - Levine Cancer Center — Charlotte, North Carolina
- Duke University — Durham, North Carolina
- Atrium Health Wake Forest Baptist Medical Center — Winston-Salem, North Carolina
- Cleveland Clinic — Cleveland, Ohio
- Ohio State University — Columbus, Ohio
- Oregon Health & Science University — Portland, Oregon
- MD Anderson Cancer Center — Houston, Texas
- University of Washington - Fred Hutchinson Cancer Research Center — Seattle, Washington
📞 Contact the Study Coordinator
Phone: (800) 664-4580
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Polycythemia Vera (PV)
- MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial — New York, New York
- A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms — Denver, Colorado
Explore by condition: All Polycythemia Vera (PV) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.